-
Tongjitang Chinese Medicines Company Reports Q4 EPS of $0.08
Friday, March 25, 2011 - 4:02pm | 83Tongjitang Chinese Medicines Company (NYSE: TCM) today announced its financial results for the quarter ended December 31, 2010. Net revenue from continuing operations(i) increased 33.6% to RMB 188.8 million ($28.6 million)(ii), from RMB 141.3 million in the prior year period. Total net income...
-
March Market Madness: Merck (MRK)
Friday, March 25, 2011 - 3:35pm | 284As we mentioned earlier, this month we are going to be looking at the stocks that make up the DJIA. . Next up – Merrk (MRK). Over the last few weeks we4 have started with a discussion of some of the more important features of our “OneSheet” stock overviews. Now we are going to present [...]
-
Did Bristol-Myers Just Find A Cure For Melanoma? (BMY)
Friday, March 25, 2011 - 1:25pm | 361PR Newswire has reported that the FDA has approved the Bristol-Myer's (NYSE: BMY) drug ipilimuab, a treatment for advanced melanoma. Yervoy, the drug's brand name, will be the only drug on the market designed to treat metastatic melanoma. Yervoy works by immunotherapy, stimulating the immune system...
-
Did Bristol-Myers Just Find A Cure For Melanoma? (BMY)
Friday, March 25, 2011 - 1:25pm | 361PR Newswire has reported that the FDA has approved the Bristol-Myer's (NYSE: BMY) drug ipilimuab, a treatment for advanced melanoma. Yervoy, the drug's brand name, will be the only drug on the market designed to treat metastatic melanoma. Yervoy works by immunotherapy, stimulating the immune system...
-
FDA Approves Bristol-Myers Squibb Drug Yervoy To Treat Melanoma
Friday, March 25, 2011 - 12:44pm | 126The FDA has approved a new drug from Bristol-Myers Squibb Co. (NYSE: BMY) to treat patients with metastaticor late-stage melanomar. The drug, ipilimumab, will be sold under the brand name Yervoy. Analysts have predicted the product will eventually reach sales topping $1 billion annually. "Yervoy...
-
FDA Approves Bristol Myers Squibb's Drug Yermoy To Treat Melanoma (BMY)
Friday, March 25, 2011 - 12:08pm | 20FDA Approves Bristol Myers Squibb's Drug Yermoy To Treat Melanoma (NYSE: BMY)
-
Bristol Myers Squibb Receives Positive FDA News (BMY)
Friday, March 25, 2011 - 12:04pm | 17Bristol Myers Squibb Receives Positive FDA News (NYSE: BMY).
-
Oppenheimer Reports New Soliris Opportunities To Become Clearer In 2H11 For Alexion
Friday, March 25, 2011 - 9:08am | 167According to Oppenheimer, Alexion Pharmaceuticals' (NASDAQ: ALXN) new Soliris opportunities are likely to become clearer in 2H11. Oppenheimer reported that it has extensively reviewed potential new indications for Soliris, beyond PNH/aHUS/renal transplant, ahead of multiple proof-of-concept data...
-
Goldman Sachs Says Buy Bristol-Myers Squibb Company (BMY)
Friday, March 25, 2011 - 8:53am | 187Goldman Sachs says to buy Bristol-Myers Squibb Company (NYSE: BMY) ahead of the release of ipi PDUFA. Goldman has a $30 price target on shares. In a note to clients, Goldman writes, "We expect an on time FDA approval for ipi (renamed Yervoy) on its March 26 PDUFA for advanced melanoma in patient...
-
Morgan Stanley Reports Two Sources Of Upside For Watson Pharmaceuticals
Friday, March 25, 2011 - 8:18am | 122According to Morgan Stanley, Watson Pharmaceuticals (NYSE: WPI) has two sources of upside. Morgan Stanley reported that it is not changing its estimates given conservative Fentora assumptions (it had been modeling that Fentora would contribute less than 0.5% of its 2011E total WPI revenues of $4....
-
Goldman Sachs Anticipates BMY Melanoma Drug Approval
Friday, March 25, 2011 - 7:58am | 157Goldman Sachs expects an on time FDA approval for Bristol-Myers Squibb Company (NYSE: BMY) ipi (renamed Yervoy) on its March 26 PDUFA for advanced melanoma in patient who have had prior therapy with REMS (second line) due to compelling data from study 020 and unmet medical need. “There is a chance...
-
J.P. Morgan Reports PG And TEVA Announce A JV
Friday, March 25, 2011 - 7:44am | 166J.P. Morgan has issued a report on the announced JV between Procter & Gamble (NYSE: PG) and Teva Pharmaceutical Industries (NASDAQ: TEVA). According to the report, "Procter has often talked about its desire to grow the OTC platform and partnering with outside companies to improve product...
-
Citi Comments On MRK's Return Of Betrixaban, Maintains EPS Estimate
Friday, March 25, 2011 - 7:33am | 133Citi is maintaining its EPS estimates on Merck (NYSE: MRK). “As expected, Merck returned the worldwide rights to betrixaban, an oral factor Xa inhibitor (anticoagulant) for patients with atrial fibrillation (AF), back to Portola after a pipeline portfolio review,” Citi writes. “We view the...
-
Merck Announces FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
Thursday, March 24, 2011 - 4:00pm | 57The Food and Drug Administration (FDA) today approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older. Zostavax is manufactured by Merck &...
-
Teva Pharmaceuticals Enters Partnership with Procter & Gamble
Thursday, March 24, 2011 - 2:19pm | 135Teva Pharmaceuticals (NASDAQ: TEVA) shares are rising after the company announced it has signed an agreement with Proctor & Gamble (NYSE: PG) to create a partnership that will combine both companies' over-the-counter medicine divisions. If you think that the stock won't fall by too much in the...